Abstract: This article analyzes the composition and characteristics of echo signals in a pseudorandom-coded ground-penetrating radar (GPR). Based on these characteristics, an innovative low-rank ...
Abstract: An improved variant of the precise-integration time-domain (PITD) method is proposed to eliminate the inverse matrix calculation and optimize the storage burden with the help of sparse ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic ...